JGC
SWTX

J. Goldman & Co’s SpringWorks Therapeutics SWTX Stock Holding History

J. Goldman & Co’s Portfolio SWTX Stock Details SWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-54,000
Closed -$2.66M – 586
2024
Q1 		$2.66M Buy
+54,000
New +$2.5M 0.09% 200

Other funds holding SWTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TAL
TIG Advisors LLC New York $2.16B AUM 72.99% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
FTCM
First Trust Capital Management Chicago, Illinois $1.9B AUM 58.39% 1-Year Est. Return

J. Goldman & Co's SWTX Position: Q2 2025 in Review

J. Goldman & Co sold out of SpringWorks Therapeutics (SWTX) in Q2 2025, closing a stake of 15,951 shares — an estimated $704K sold.

J. Goldman & Co first reported a position in SWTX in Q1 2024 and held it in 5 quarters. The position peaked at $8.51M in Q2 2024. 222 funds tracked by Wall St. Rank hold SWTX as of Q2 2025.

  • J. Goldman & Co reported no remaining SpringWorks Therapeutics position as of Q2 2025 after selling out during the quarter.
  • J. Goldman & Co sold 15,951 SpringWorks Therapeutics shares in Q2 2025, an estimated $704K.
  • J. Goldman & Co first reported a position in SpringWorks Therapeutics in Q1 2024 and held it in 5 quarters.
  • J. Goldman & Co's SpringWorks Therapeutics position peaked at $8.51M in Q2 2024.
  • 222 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q2 2025.

Based on J. Goldman & Co's 13F filing for Q2 2025, filed 14 Aug 2025.